http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. (HealthDay)—Sometimes, simply watching and waiting is a safe alternative to surgery for older patients with small kidney tumors, a new study suggests. http://medicalxpress.com/news/2013-02-approach-older-patients-kidney-cancer.html Cancer Wed, 13 Feb 2013 05:40:01 EST news279952397 Survival for advanced stomach and oesophagael cancer patients increases by 40 per cent when treated with the chemotherapy drug, Docetaxel – providing evidence to prescribe it as a second-line treatment, according to the results of a Cancer Research UK trial presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal cancers symposium today (Wednesday). http://medicalxpress.com/news/2013-01-docetaxel-significantly-survival-incurable-gastric.html Cancer Wed, 23 Jan 2013 06:28:22 EST news278144892 A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. http://medicalxpress.com/news/2013-01-drug-combination-pancreatic-cancer-patient.html Cancer Tue, 22 Jan 2013 18:00:01 EST news278097991 (HealthDay)—The American Society of Clinical Oncology has issued updated recommendations for both the prevention and management of febrile episodes in neutropenic oncology outpatients; the recommendations have been published online Jan. 14 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2013-01-asco-issues-guideline-febrile-neutropenia.html Cancer Tue, 15 Jan 2013 13:08:16 EST news277477682 New guidelines from the American Cancer Society say evidence is sufficient to recommend screening high risk patients for lung cancer with low-dose computed tomography (CT) provided that certain conditions exist: http://medicalxpress.com/news/2013-01-american-cancer-society-decision-lung.html Cancer Fri, 11 Jan 2013 10:10:48 EST news277121439 Given the right equipment, training and skill, an individual surgeon can expect to provide the best possible care on a consistent basis. But how do you get an entire system of surgeons—each with his or her own ideas, backgrounds, and routines—to provide that same level of care? http://medicalxpress.com/news/2012-11-intermountain-healthcare-cancer-road.html Health Fri, 30 Nov 2012 10:40:22 EST news273494411 About 70 percent of women who have both breasts removed following a breast cancer diagnosis do so despite a very low risk of facing cancer in the healthy breast, new research from the University of Michigan Comprehensive Cancer Center finds. http://medicalxpress.com/news/2012-11-women-mastectomy-dont.html Cancer Tue, 27 Nov 2012 18:34:27 EST news273263597 A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the Translational Genomics Research Institute (TGen). http://medicalxpress.com/news/2012-11-phase-iii-worldwide-drug-patients.html Cancer Mon, 19 Nov 2012 13:14:23 EST news272553254 (HealthDay)—A new device meant to help surgeons determine in the operating room if they have removed all cancerous breast cancer tissue may help reduce repeat surgeries after lumpectomy without compromising cosmetic effects, according to a new study. http://medicalxpress.com/news/2012-09-device-breast-cancer-surgeries.html Cancer Wed, 12 Sep 2012 12:10:01 EST news266666143 (HealthDay)—In a new study, three types of screening methods used to determine whether breast cancer has spread to other parts of the body only spotted a small portion of tumors that had done so. http://medicalxpress.com/news/2012-09-screens-breast-cancer.html Cancer Wed, 12 Sep 2012 11:50:01 EST news266666109 Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago. http://medicalxpress.com/news/2012-09-crizotinib-tumor-size-patients-alk.html Cancer Thu, 06 Sep 2012 15:07:50 EST news266162854 A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient survival rates, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC), and The University of Chicago. http://medicalxpress.com/news/2012-09-marital-status-survival-significantly-stage.html Cancer Thu, 06 Sep 2012 15:07:01 EST news266162815 Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago. http://medicalxpress.com/news/2012-09-standard-chemotherapy-higher-survival-experimental.html Cancer Thu, 06 Sep 2012 15:04:23 EST news266162654 Analysis of non-small cell lung cancer (NSCLC) patient records in the California Cancer Registry (CCR) database during the 20-year period of 1988-2008 indicates that Hispanics/Latinos with NSCLC have a higher overall survival compared to non-Hispanic white patients, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC), and The University of Chicago. http://medicalxpress.com/news/2012-09-hispanic-lung-cancer-patients-higher.html Cancer Thu, 06 Sep 2012 15:01:35 EST news266162489 Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); however, this study did not show an improvement in overall survival with PCI, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago. http://medicalxpress.com/news/2012-09-brain-lung-cancer-treatment.html Cancer Thu, 06 Sep 2012 13:47:21 EST news266158033 Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago. http://medicalxpress.com/news/2012-09-adding-bavituximab-second-line-chemotherapy-response.html Cancer Thu, 06 Sep 2012 13:40:30 EST news266157617 Stage I, non-small cell lung cancer (NSCLC) patients who received radiation therapy have an increased median survival of 21 months compared to 16 months, and the percentage of patients who receive no treatment declined from 20 percent to 16 percent, respectively, when comparing the two eras evaluated, 1999-2003 and 2004-2008, according to detailed analysis of the SEER-17 (Surveillance Epidemiology and End Results, National Cancer Institute) national database presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago. http://medicalxpress.com/news/2012-09-stage-nsclc-patients-therapy-surviving.html Cancer Thu, 06 Sep 2012 13:39:42 EST news266157535 (HealthDay) -- It remains unclear whether the benefits of prostate-specific antigen (PSA) testing outweigh the harms, but evidence suggests that men with a longer life expectancy may benefit from testing, according to a provisional clinical opinion from the American Society of Clinical Oncology published online July 16 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-07-benefits-prostate-specific-antigen-unclear.html Cancer Fri, 20 Jul 2012 13:20:01 EST news262003483 (HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy, according to the results of a phase III study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago. http://medicalxpress.com/news/2012-06-asco-avastin-2nd-line-chemo-ups.html Cancer Tue, 05 Jun 2012 13:30:01 EST news258120168 (HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free and overall survival, compared with chemotherapy, according to a study published online June 4 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago. http://medicalxpress.com/news/2012-06-asco-trametinib-survival-metastatic-melanoma.html Cancer Tue, 05 Jun 2012 04:10:01 EST news258086357 A critical shortage of generic drugs in the United States, particularly in cancer care, could be curbed with legislation now being hammered out by the US House and Senate, doctors said on Monday. http://medicalxpress.com/news/2012-06-legislation-aims-curb-cancer-drug.html Medications Mon, 04 Jun 2012 15:40:01 EST news258042450 An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center. http://medicalxpress.com/news/2012-06-immune-therapy-kidney-cancer.html Cancer Mon, 04 Jun 2012 15:05:25 EST news258040919 A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA. http://medicalxpress.com/news/2012-06-drug-combination-highly-effective-newly.html Cancer Mon, 04 Jun 2012 10:35:14 EST news258024905 (HealthDay) -- Even in the field of cancer treatment, sometimes newer isn't necessarily better. http://medicalxpress.com/news/2012-06-older-drug-advanced-breast-cancer.html Cancer Mon, 04 Jun 2012 09:40:02 EST news258020025 (HealthDay) -- Girls who receive radiation to the chest to treat childhood cancer, even those getting lower doses, have a high risk of developing breast cancer at a young age, according to a new study. http://medicalxpress.com/news/2012-06-chest-girls-greater-early-breast.html Cancer Mon, 04 Jun 2012 09:12:21 EST news258019931 High doses of the herb American ginseng (Panax quinquefolius) over two months reduced cancer-related fatigue in patients more effectively than a placebo, a Mayo Clinic-led study found. Sixty percent of patients studied had breast cancer. The findings are being presented at the American Society of Clinical Oncology's annual meeting. http://medicalxpress.com/news/2012-06-ginseng-fatigue-cancer-patients.html Cancer Mon, 04 Jun 2012 09:00:02 EST news257925842 (HealthDay) -- Teenagers and young adults with acute lymphoblastic leukemia, a cancer of the blood and bone marrow, are more likely to relapse and less likely to survive than younger children with the disease, according to a new study. http://medicalxpress.com/news/2012-06-leukemia-deadlier-teens-young-adults.html Cancer Sat, 02 Jun 2012 15:10:01 EST news257862687 A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday. http://medicalxpress.com/news/2012-06-drug-cocktail-boosts-ovarian-cancer.html Cancer Sat, 02 Jun 2012 13:23:52 EST news257862174 Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American and Caucasian patients. This data will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from Friday through Tuesday (June 1-5) in Chicago, IL. http://medicalxpress.com/news/2012-06-dna-marker-differences-breast-cancer.html Cancer Sat, 02 Jun 2012 13:07:08 EST news257861219 Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications. Treating these patients with a combination of drugs has the potential to improve outcomes compared to treatment with lapatinib alone, but it has not been clear whether the additional benefits outweigh the risks. Now, researchers from Fox Chase Cancer Center and their international collaborators will present information at the 2012 Annual Meeting of the American Society of Clinical Oncology on Saturday, June 2 that will give clinicians the information needed to make that call. http://medicalxpress.com/news/2012-06-combination-treatment-lapatinib-pazopanib-doesnt.html Cancer Fri, 01 Jun 2012 19:31:51 EST news257797903